All News

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for autologous stem cell transplant.

Dr. Anne Peled shares advice for patients and dispelled myths related to cancer survivorship.

If you’re struggling out there, feeling a little broken inside, I see you. And if you’re not, man, I wish I were you.

As patients with advanced cancer near the end of life, reducing unnecessary medications may help prioritize comfort, quality of life and symptom relief.

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

This weekend, January 30 - February 1, join thousands of runners, walkers, survivors and spectators for the 19th Annual DONNA Marathon Weekend.

Among patients with advanced breast cancer, levels of circulating tumor DNA before treatment may predict their response to targeted therapy.

Patients with recurrent or progressive high-grade meningioma had encouraging responses to Verzenio in a phase 2 trial.

A 27-year brain tumor survivor shares how mindset, resilience and purposeful action helped her thrive beyond what cancer statistics predicted.

The FDA cleared a phase 3 trial of iSCIB1+ for advanced melanoma after phase 2 data showed improved progression free survival versus standard care.

Stage 2 essential thrombocythemia is a slow-growing blood cancer managed with monitoring or treatment to reduce clot risk and control symptoms.

Newly diagnosed with cancer? This oncofertility guide covers egg freezing, sperm banking, and critical questions for your oncologist.

Receiving a diagnosis of squamous cell carcinoma can be an overwhelming experience, but it is important to remember that you are not alone.

Small cell lung cancer grows quickly. Learn how it’s diagnosed, staged and treated, and what patients can expect from therapies and side effects.

Patients should understand their cancer, treatment goals and options and record questions to support informed, productive discussions with care teams.

For Ashliann Mazeika, a diagnosis at 24 led to a decade-long treatment journey affirmed by the Breast Cancer Index test.

After five years in remission, a scan shows a small anomaly that might be recurrence, or it can show nothing, leaving a tense week before my oncologist visit.

FDA granted breakthrough therapy designation to sofetabart mipitecan for adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.

The FDA approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Braftovi with Erbitux and chemotherapy.

MammaPrint and BluePrint tests may help identify HR+/HER2– early-stage breast cancer patients likely to benefit from anthracycline-based chemotherapy.

Long-term CATNON trial results show radiotherapy followed by adjuvant temozolomide extends survival in patients with newly diagnosed anaplastic glioma.

Stick your toes in the ocean. Feed the koi. Play make-believe carwash with a toddler. Hold his hand because he asks you to. Be present.

Dr. Anne Peled co-developed the sensation-preserving mastectomy she received after her second diagnosis of breast cancer.

Experts highlight key themes from the ASCO GI Cancers Symposium, including the growing role of AI and an increased emphasis on patient-centered decision-making.

Outpatient CD19 CAR-NK plus rituximab led to complete remissions up to 15 months in patients with Waldenström Non-Hodgkin lymphoma.

The allogeneic CAR-T therapy aims to expand urgently needed options for children and adults with aggressive T-cell blood cancers.

The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare blood cancer.

CURE spoke with advocate Karen Hoyt about liver cancer, liver disease, and liver health, highlighting silent risk, misconceptions and need for awareness.